ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models
Emma Polonio-Alcalá, Sònia Solé-Sánchez, Pau Muñoz-Guardiola, Elisabet Megías-Roda, Héctor Perez-Montoyo, Marc Yeste-Velasco, Jose Alfón, Jose Miguel Lizcano, Carles Domènech, Santiago Ruiz-Martínez, Teresa Puig, Emma Polonio-Alcalá, Sònia Solé-Sánchez, Pau Muñoz-Guardiola, Elisabet Megías-Roda, Héctor Perez-Montoyo, Marc Yeste-Velasco, Jose Alfón, Jose Miguel Lizcano, Carles Domènech, Santiago Ruiz-Martínez, Teresa Puig
No abstract availableKeywords: ABTL0812; Autophagy; Breast Cancer; Chemoresistance; TRIB3; Targeted Therapy.
Conflict of interest statement
Sònia Solé‐Sánchez, Pau Muñoz‐Guardiola, Elisabet Megías‐Roda, Héctor Perez‐Montoyo, Marc Yeste‐Velasco, Jose Alfón, and Carles Domènech are Ability Pharmaceuticals employees; Jose Miguel Lizcano is an advisory board member and Carles Domènech holds shares of the company.
Figures
References
- Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple‐negative breast cancer: a review. Breast Cancer Res Treat. 2018;169(3):397‐406.
- Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple‐negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429‐4434.
- Lehmann BDB, Bauer JAJ, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple‐negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750‐2767.
- Erazo T, Lorente M, López‐Plana A, Muñoz‐Guardiola P, Fernández‐Nogueira P, García‐Martínez JA, et al. The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles‐3 Pseudokinase. Clin Cancer Res. 2016;22(10):2508‐2519.
- López‐Plana A, Fernández‐Nogueira P, Muñoz‐Guardiola P, Solé‐Sánchez S, Megías‐Roda E, Pérez‐Montoyo H, et al. The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer. Int J Cancer. 2020;147 (4):1163‐1179.
- Muñoz‐Guardiola P, Casas J, Megías‐Roda E, Solé S, Perez‐Montoyo H, Yeste‐Velasco M, et al. The anti‐cancer drug ABTL0812 induces ER stress‐mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. Autophagy. 2021;17(6):1349‐1366.
- París‐Coderch L, Soriano A, Jiménez C, Erazo T, Muñoz‐Guardiola P, Masanas M, et al. The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress‐mediated autophagy and apoptosis. Cell Death Dis. 2020;11(9):1‐10.
- Felip I, Moiola CP, Megino‐Luque C, Lopez‐Gil C, Cabrera S, Solé‐Sánchez S, et al. Therapeutic potential of the new TRIB3‐mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. Gynecol Oncol. 2019;153(2):425‐435.
- Chakravarty G, Mathur A, Mallade P, Gerlach S, Willis J, Datta A, et al. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF‐7/Dox breast cancer cells. Biochimie. 2016;124:53‐64.
- Chang CH, Bijian K, Wernic D, Su J, da Silva SD, Yu H, et al. A novel orally available seleno‐purine molecule suppresses triple‐negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. Autophagy. 2019;15(8):1376‐1390.
Source: PubMed